•Dr. Reddy's Laboratories announced a temporary delay in commercial supplies of semaglutide injection due to a scale-up issue with the active pharmaceutical ingredient.
•Management emphasized that products already in the market are unaffected, with no patient safety concerns or risk of product recall.
•DarioHealth expects the deployment of its DarioIQ AI platform to increase annual recurring revenue from existing customers by approximately 10% to 15%.
